Xiaoli Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaoli Yu has a total of 179 co-authors. Here are the top co-authors by number of shared publications:
- Jing Liu
Fudan University Shanghai Cancer Center 1 Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai Shanghai, China
28 shared publications - Moran Chen
Key Laboratory of Breast Cancer in Shanghai Department of Breast Surgery Fudan University Shanghai Cancer Center Shanghai China
28 shared publications - Xupeng Hou
Department of Pancreatic Cancer, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, P.R. China
28 shared publications - Hongxia Sun
State Key Laboratory for Structural Chemistry of Unstable and Stable Species, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China
27 shared publications - Jihui Hao
Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin’s Clinical Research Center for Cancer, China
27 shared publications - Lin Li
Tianjin Medical University Cancer Institute and Hospital 3 Department of Pancreatic Cancer National Clinical Research Center for Cancer, Tianjin, China
27 shared publications
Latest Publications
- Open Access
Abscopal Effect in Radiation Therapy: The Immune Mechanisms and Clinical Advances
The abscopal effect is a systemic antitumor response to localized radiotherapy (RT) that has emerged as a central focus in the era of immunotherapy. Clinical evidence demonstrates that local RT can induce regression of distant, nonirradiated metastases, including cases of complete remission. However, the effect remains unpredictable, with marked variation in clinical outcomes ranging from complete regression to paradoxical progression. The mechanistic basis for this heterogeneity and optimal strategies to enhance abscopal effects remain incompletely understood. This review synthesizes current evidence into a mechanistic framework organized around a three‐stage immune cascade: ignition, orchestration, and execution. We examine how tumor‐intrinsic factors, RT parameters, and biomarkers shape this cascade. We then appraise the clinical trial landscape and discuss how these mechanistic insights may inform patient selection, treatment timing, and radioimmunotherapy combination strategies. Critically, we establish a bidirectional framework distinguishing the favorable abscopal response from the pro‐tumorigenic badscopal effect, in which RT paradoxically promotes distant progression through immunosuppressive pathways. By clarifying these mechanisms and variables, this review offers a framework for improving future clinical trial design and advancing the abscopal effect from a sporadically observed phenomenon to a predictable therapeutic strategy.
Open AccessAbscopal Effect in Radiation Therapy: The Immune Mechanisms and Clinical Advances
The abscopal effect is a systemic antitumor response to localized radiotherapy (RT) that has emerged as a central focus in the era of immunotherapy. Clinical evidence demonstrates that local RT can induce regression of distant, nonirradiated metastases, including cases of complete remission. However, the effect remains unpredictable, with marked variation in clinical outcomes ranging from complete regression to paradoxical progression. The mechanistic basis for this heterogeneity and optimal strategies to enhance abscopal effects remain incompletely understood. This review synthesizes current evidence into a mechanistic framework organized around a three‐stage immune cascade: ignition, orchestration, and execution. We examine how tumor‐intrinsic factors, RT parameters, and biomarkers shape this cascade. We then appraise the clinical trial landscape and discuss how these mechanistic insights may inform patient selection, treatment timing, and radioimmunotherapy combination strategies. Critically, we establish a bidirectional framework distinguishing the favorable abscopal response from the pro‐tumorigenic badscopal effect, in which RT paradoxically promotes distant progression through immunosuppressive pathways. By clarifying these mechanisms and variables, this review offers a framework for improving future clinical trial design and advancing the abscopal effect from a sporadically observed phenomenon to a predictable therapeutic strategy.
- Open Access
- 4 August 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1880437
Predictors of survival in triple-negative breast cancer patients treated with neoadjuvant chemotherapy, surgery, and radiotherapy
Background: Triple-negative breast cancer (TNBC) is known for its heterogeneity. Due to the small sample sizes in prior studies, there is limited understanding of whether different molecular subtypes have distinct predictive values following comprehensive treatment. Methods: Females with TNBC treated with neoadjuvant chemotherapy (NAC), surgery, and radiotherapy from 2019 to 2022 were retrospectively analyzed. Disease-free survival (DFS) and overall survival (OS) were evaluated using the Kaplan-Meier method to compare the basal-like immune-suppressed (BLIS) and non-BLIS subtypes. Univariate and multivariate Cox analyses were employed to identify prognostic factors for DFS. Results: The median follow-up time was 34 months. The 4-year DFS rates for non-BLIS and BLIS subtypes were 74.8% and 56.1%, respectively (P = .035). Independent predictors of DFS included molecular subtype (HR = 2.071, P = .034) and ypN status (HR for ypN1-2 = 4.891, P = .018; ypN3 = 7.444, P = .008). Additionally, both nodal stage and lymph node ratio categories (LNRC) were negatively correlated with DFS in both subgroups (P <.001 for both). Moreover, in the BLIS group, there was a statistically significant difference between low and high LNR (P < 0.05), while in the non-BLIS group, DFS differed significantly across subgroups with low, intermediate, or high LNRC (P < 0.05). Conclusions: Molecular subtyping plays a crucial role in prognosis, with the non-BLIS subtype showing more favorable outcomes. The presence of residual nodal disease post-NAC helps distinguish between favorable and unfavorable outcomes in different TNBC subtypes. These findings underscore the importance of developing more individualized radiotherapy strategies following NAC for each molecular subtype.
- 4 August 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1880437
Open AccessPredictors of survival in triple-negative breast cancer patients treated with neoadjuvant chemotherapy, surgery, and radiotherapy
Background: Triple-negative breast cancer (TNBC) is known for its heterogeneity. Due to the small sample sizes in prior studies, there is limited understanding of whether different molecular subtypes have distinct predictive values following comprehensive treatment. Methods: Females with TNBC treated with neoadjuvant chemotherapy (NAC), surgery, and radiotherapy from 2019 to 2022 were retrospectively analyzed. Disease-free survival (DFS) and overall survival (OS) were evaluated using the Kaplan-Meier method to compare the basal-like immune-suppressed (BLIS) and non-BLIS subtypes. Univariate and multivariate Cox analyses were employed to identify prognostic factors for DFS. Results: The median follow-up time was 34 months. The 4-year DFS rates for non-BLIS and BLIS subtypes were 74.8% and 56.1%, respectively (P = .035). Independent predictors of DFS included molecular subtype (HR = 2.071, P = .034) and ypN status (HR for ypN1-2 = 4.891, P = .018; ypN3 = 7.444, P = .008). Additionally, both nodal stage and lymph node ratio categories (LNRC) were negatively correlated with DFS in both subgroups (P <.001 for both). Moreover, in the BLIS group, there was a statistically significant difference between low and high LNR (P < 0.05), while in the non-BLIS group, DFS differed significantly across subgroups with low, intermediate, or high LNRC (P < 0.05). Conclusions: Molecular subtyping plays a crucial role in prognosis, with the non-BLIS subtype showing more favorable outcomes. The presence of residual nodal disease post-NAC helps distinguish between favorable and unfavorable outcomes in different TNBC subtypes. These findings underscore the importance of developing more individualized radiotherapy strategies following NAC for each molecular subtype.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Table S10 from The SDC1–ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance
Splenic immunoglobulin-secreting cells quantified by ELISpot
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S10 from The SDC1–ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance
Splenic immunoglobulin-secreting cells quantified by ELISpot
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S12 from The SDC1–ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance
Lactate mediates SDC1/ENO1-induced regulation of stemness, immune evasion, and radioresistance
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from The SDC1–ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance
Lactate mediates SDC1/ENO1-induced regulation of stemness, immune evasion, and radioresistance
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S13 from The SDC1–ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance
SDC1 protects ENO1 from degradation (related to Fig. 6)
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S13 from The SDC1–ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance
SDC1 protects ENO1 from degradation (related to Fig. 6)
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Data from The SDC1–ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance
Radiotherapy (RT) resistance remains a major barrier to effective treatment of triple-negative breast cancer (TNBC), highlighting the need to identify mechanisms driving resistance. In this study, we identified syndecan-1 (SDC1) as a pivotal mediator of cancer-associated fibroblast (CAF)–induced radioresistance in breast cancer. SDC1 bound the TIM barrel domain of the glycolytic enzyme enolase 1 (ENO1), preventing FBXW7-mediated degradation and driving aerobic glycolysis and lactate accumulation. The resulting lactate-rich microenvironment not only promoted tumor stemness but also significantly impaired the cytotoxic functions of both NK cells and CD8+ T cells. Pharmacologic inhibition of ENO1 or lactate export restored radiosensitivity. Targeting SDC1+ CAFs with the antibody–drug conjugate indatuximab ravtansine (BT062) synergized with RT in vivo, markedly reducing tumor burden, depleting stem-like tumor cells, and remodeling the immune microenvironment. These findings define a CAF metabolic program that fuels tumor stemness and rewires the immune microenvironment to confer radioresistance, supporting the therapeutic targeting of SDC1+ CAFs in TNBC.Significance:SDC1-mediated ENO1 stabilization in cancer-associated fibroblasts promotes breast cancer radioresistance by reprograming metabolism to enhance lactate production that fuels tumor stemness and immunosuppression, highlighting the potential of targeting SDC1 to restore radiosensitivity.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from The SDC1–ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance
Radiotherapy (RT) resistance remains a major barrier to effective treatment of triple-negative breast cancer (TNBC), highlighting the need to identify mechanisms driving resistance. In this study, we identified syndecan-1 (SDC1) as a pivotal mediator of cancer-associated fibroblast (CAF)–induced radioresistance in breast cancer. SDC1 bound the TIM barrel domain of the glycolytic enzyme enolase 1 (ENO1), preventing FBXW7-mediated degradation and driving aerobic glycolysis and lactate accumulation. The resulting lactate-rich microenvironment not only promoted tumor stemness but also significantly impaired the cytotoxic functions of both NK cells and CD8+ T cells. Pharmacologic inhibition of ENO1 or lactate export restored radiosensitivity. Targeting SDC1+ CAFs with the antibody–drug conjugate indatuximab ravtansine (BT062) synergized with RT in vivo, markedly reducing tumor burden, depleting stem-like tumor cells, and remodeling the immune microenvironment. These findings define a CAF metabolic program that fuels tumor stemness and rewires the immune microenvironment to confer radioresistance, supporting the therapeutic targeting of SDC1+ CAFs in TNBC.Significance:SDC1-mediated ENO1 stabilization in cancer-associated fibroblasts promotes breast cancer radioresistance by reprograming metabolism to enhance lactate production that fuels tumor stemness and immunosuppression, highlighting the potential of targeting SDC1 to restore radiosensitivity.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from The SDC1–ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance
Independent validation of elevated stromal SDC1 expression in breast cancer
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from The SDC1–ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance
Independent validation of elevated stromal SDC1 expression in breast cancer
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Table S11 from The SDC1–ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance
Serum immunoglobulin levels in treated mice (ELISA)
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S11 from The SDC1–ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance
Serum immunoglobulin levels in treated mice (ELISA)
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S14 from The SDC1–ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance
Evaluation of adverse events associated with anti-SDC1 antibody–drug conjugate monotherapy and combination therapy (related to Fig. 8)
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S14 from The SDC1–ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance
Evaluation of adverse events associated with anti-SDC1 antibody–drug conjugate monotherapy and combination therapy (related to Fig. 8)
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from The SDC1–ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance
SDC1⁺ CAFs promote cancer stemness and enhance radioresistance
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from The SDC1–ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance
SDC1⁺ CAFs promote cancer stemness and enhance radioresistance